Glucose 6-P dehydrogenase delays the onset of frailty by protecting against muscle damage

Coralie Arc-chagnaud, Andrea Salvador-pascual, Esther Garcia-dominguez, Gloria Olaso-gonzalez, Angela G Correas, Eva Serna, Thomas Brioche, Angele Chopard, Pablo J Fernandez-marcos, Manuel Serrano, et al.

To cite this version:

Coralie Arc-chagnaud, Andrea Salvador-pascual, Esther Garcia-dominguez, Gloria Olaso-gonzalez, Angela G Correas, et al.. Glucose 6-P dehydrogenase delays the onset of frailty by protecting against muscle damage. Journal of Cachexia, Sarcopenia and Muscle, Wiley Open Access/Springer Verlag, 2021, Online, 18p. 10.1002/jcsm.12792. hal-03418649

HAL Id: hal-03418649
https://hal.inrae.fr/hal-03418649
Submitted on 8 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives| 4.0 International License
Glucose 6-P dehydrogenase delays the onset of frailty by protecting against muscle damage

Coralie Arc-Chagnaud¹, Andrea Salvador-Pascual¹,², Esther Garcia-Dominguez¹, Gloria Olaso-Gonzalez⁴,⁹, Angela G. Correas¹, Eva Serna¹, Thomas Brioche³, Angele Chopard³, Pablo J. Fernandez-Marcos⁴, Manuel Serrano⁵,⁶, Antonio L. Serrano⁷, Pura Muñoz-Cánoves⁵,⁷,⁸, Vicente Sebastiá⁹, Jose Viña¹

© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Abstract

Background Frailty is a major age-associated syndrome leading to disability. Oxidative damage plays a significant role in the promotion of frailty. The cellular antioxidant system relies on reduced nicotinamide adenine dinucleotide phosphate (NADPH) that is highly dependent on glucose 6-P dehydrogenase (G6PD). The G6PD-overexpressing mouse (G6PD-Tg) is protected against metabolic stresses. Our aim was to examine whether this protection delays frailty.

Methods Old wild-type (WT) and G6PD-Tg mice were evaluated longitudinally in terms of frailty. Indirect calorimetry, transcriptomic profile, and different skeletal muscle quality markers and muscle regenerative capacity were also investigated.

Results The percentage of frail mice was significantly lower in the G6PD-Tg than in the WT genotype, especially in 26-month-old mice where 50% of the WT were frail vs. only 13% of the Tg ones (P < 0.001). Skeletal muscle transcriptomic analysis showed an up-regulation of respiratory chain and oxidative phosphorylation (P = 0.009) as well as glutathione metabolism (P = 0.035) pathways in the G6PD-Tg mice. Accordingly, the Tg animals exhibited an increase in reduced glutathione (34.5%, P < 0.01) and a decrease on its oxidized form (−69%, P < 0.05) and in lipid peroxidation (4-HNE: −20.5%, P < 0.05). The G6PD-Tg mice also showed reduced apoptosis (BAX/Bcl2: −25.5%, P < 0.05; and Bcl-xl: −20.5%, P < 0.05), lower levels of the intramuscular adipocyte marker FABP4 (−54.7%, P < 0.05), and increased markers of mitochondrial content (COX IV: 89.7%, P < 0.05; Grp75: 37.8%, P < 0.05) and mitochondrial OXPHOS complexes (CII: 81.25%, P < 0.01; CIII: 52.5%, P < 0.01; and CIV: 37.2%, P < 0.05). Energy expenditure (−4.29%, P < 0.001) and the respiratory exchange ratio were lower (−13.4%, P < 0.0001) while the locomotor activity was higher (43.4%, P < 0.0001) in the 20-month-old Tg, indicating a major energetic advantage in these mice. Short-term exercise training in young C57BL/6J mice induced a robust activation of G6PD in skeletal muscle (203.4%, P < 0.05), similar to that achieved in the G6PD-Tg mice (142.3%, P < 0.01).

Conclusions Glucose 6-P dehydrogenase deficiency can be an underestimated risk factor for several human pathologies and even frailty. By overexpressing G6PD, we provide the first molecular model of robustness. Because G6PD is regulated by pharmacological and physiological interventions like exercise, our results provide molecular bases for interventions that by increasing G6PD will delay the onset of frailty.

Keywords Aging; Antioxidant; Mitochondria; Disability; Healthspan; NADPH; Reactive oxygen species

Received: 29 September 2020; Revised: 26 July 2021; Accepted: 23 August 2021

*Correspondence to: Gloria Olaso-Gonzalez, Department of Physiology, School of Medicine, University of Valencia, Av. Blasco Ibañez 15, 46010 Valencia, Spain. Phone: +34963983266; Email: gloria.olaso@uv.es

‡ These two authors have contributed equally to the work.

§ These two authors have contributed equally as senior authors of this work.
Introduction

Frailty is a clinical geriatric syndrome characterized by a cumulative decline in multiple body systems that is associated with high vulnerability to stressors, which results in a dysregulation of multiple physiological systems. If left untreated, it progresses to disability, with enormous personal and social consequences for the patients, their caretakers, and society in general.  

Importantly, old age, although associated to frailty, does not define frailty itself. Despite advanced age, some persons remain vigorous, while others have gradual functional decline in the absence of apparent diseases. A person who is not pre-frail or frail is considered robust. In this sense, robustness is opposed to frailty.

In our study, we aimed at delaying the onset of frailty in its generally accepted broader geriatric context.  

Age-associated damage is of low intensity, but its chronic nature eventually leads to a global decline in the biological reserve and in cellular functionality. The correlation between oxidative damage and frailty, and its mitochondrial root, has been reported in both human and animal studies. This led us to formulate the ‘free radical theory of frailty’. This theory postulates that frailty is associated with oxidative stress that acts in a dual mode: firstly, it affects the redox signalling balance that occurs in normal physiology, and secondly, if oxidative stress persists, it causes a permanent damage that provokes a failure of cell functions, especially those involved in homeostasis, that finally leads to the onset of frailty.  

Glucose 6-P dehydrogenase (G6PD) is the rate-limiting enzyme in the pentose phosphate pathway (PPP) and is ubiquitously expressed in mammalian tissues. Glucose can be catabolized via the glycolytic pathway or via the oxidative PPP to make nicotinamide adenine dinucleotide phosphate (NADPH), the ultimate donor of reductive power for the large majority of reactive oxygen species (ROS)-detoxifying enzymes. Thus, G6PD plays a central role in the antioxidant defence. Importantly, overexpression of G6PD in Drosophila melanogaster and mice leads to higher levels of NADPH and lower levels of ROS-derived damage concomitant with extended lifespan. Accordingly, G6PD deficiency, the most common human enzyme defect, is effectively managed in the clinical practice by avoiding oxidative stress. Because NADPH is at the core of the anti-ROS defence, we hypothesized that an increase in G6PD activity could protect against age-associated damage and delay the onset of frailty.

To the best of our knowledge, a molecular model of vigorousness has not yet been described. Although it has been shown that life-long overexpression of HSP70 and the growth hormone receptor knockout (GHR-KO) mice facilitate recovery after damage in muscles of old mice and enhance neuromusculoskeletal healthspan, frailty was not determined in those studies.

Here, we propose a new molecular model for the promotion of robustness, that is, the G6PD-Tg. We have characterized this mouse line and have found lower levels of ROS-derived damage and better protection against metabolic stresses.

Using our previously described test to evaluate frailty, we now show that overexpression of G6PD in mice results in a significant delay in frailty. This opens up room for intervention because by promoting G6PD expression, one can delay the onset of frailty in animals and hopefully in human beings.

The activation of the G6PD by nutritional or pharmacological interventions could have translational potential in geriatrics and in gerontological research. In fact, we report here that a physiological intervention, exercise training in C57BL/6J mice, induces an increase in the activity of G6PD in the skeletal muscle of an order of magnitude very similar to that obtained in the G6PD-Tg animals.

Our results reinforce the importance of pursuing frailty studies in humans with G6PD deficiency, an enzymopathy affecting over 400 million people in the world.

Materials and methods

Experimental animals

The animal study was approved by the University of Valencia Ethics Committee for Research and Animal Welfare (License References A1444079171882 and A1481561216420). Animals were housed at the Animal House Core Facility of the University of Valencia.

Cohorts of old (18–26 months) C57BL6 [wild-type (WT)] and G6PD-Tg mice were used to longitudinally evaluate frailty. Each frailty criteria had a designated cut-off point to identify the percentage of mice with the lowest performance. See references for details.

Young (7-month-old) and old (19- to 26-month-old) C57BL6 and G6PD-Tg mice were used to study the skeletal muscle regeneration capacity.

All the molecular and biochemical determinations were performed in 21- to 27-month-old WT and G6PD-Tg mice.

High-resolution respirometry was measured in fibre bundles in ~20-month-old WT and G6PD-Tg animals.

Very old (34-month-old) WT and G6PD-Tg mice were used to quantify the skeletal muscle fibre size in basal conditions. The exercise training experiments were performed in young C57BL/6J animals (5-month-old).

Frailty score

A score for frailty was determined at 18- to 20-month-old (WT n = 24, Tg n = 39–40), 21- to 22-month-old (WT n = 17, Tg n = 36), 23- to 24-month-old (WT n = 12–14, Tg n = 28–29),
and 25- to 26-month-old (WT n = 5–11, Tg n = 16–24) animals. Briefly, we evaluated five functional parameters: body weight, motor coordination, grip strength, running time, and speed during a treadmill test. This score was fully described previously by our research team and others.

**Muscle regeneration experiments**

The skeletal muscle regeneration was studied in control (WT n = 4; Tg n = 4) and at 4 days (WT n = 4, Tg n = 4 young; WT n = 4, Tg n = 6 old animals), 7 days (WT n = 4, Tg n = 4 young; WT n = 3, Tg n = 5 old animals), and 10 days (WT n = 4, Tg n = 4 young; WT n = 3, Tg n = 4 old animals) following cardiotoxin-induced injury as previously described.

**Histology and immunohistochemistry in muscle cryosections**

Gastrocnemius and tibialis anterior muscles were used for the analyses. Muscle samples were included in optimal cutting temperature compound (OCT), frozen in isopentane cooled with liquid nitrogen, and stored at −80°C until analysis. Transverse serial cross-sections (10 μm thick) were obtained using a cryostat maintained at −20°C (HM-560, Microm H) and mounted onto glass microscope slides. Cryosections were coloured with haematoxylin–eosin (HE) solution or immunostained using anti-eMHC antibody (F1.652, Developmental Studies Hybridoma Bank) (see Supporting Information for details).

**Digital image acquisition and processing**

Muscle sections were photographed with Axiovison software and were digitalized with the microscopic preparation scanner Panoramic Midi 3 (3DHISTECH Ltd., Budapest, Hungary) at ×20 magnification. Digitalization was performed with a PNG lossless high-compressed format due to the vast number of pixels scanned. Panoramic viewer (3DHISTECH Ltd.) was used for exporting all images in compressed JPEG (90% quality vs. compression ratio). To quantify myofibre size, at least 300 representative fibres of each sample were outlined, and their cross-sectional area was determined using ImageJ software (see Supporting Information for details).

**RNA extraction and whole transcriptomic analysis**

Total RNA from the quadriceps muscle was extracted using the TRIzol reagent. RNA integrity number (RIN) was tested by the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), and the RNA concentration was determined by measuring absorbance at 260 nm using a spectrophotometer (GeneQuant, GE Healthcare Biosciences). Ten microarrays were analysed: WT (n = 5) and G6PD-Tg (n = 5). To determine global differences in genetic profiles between groups, principal component analysis (PCA) and unsupervised hierarchical clustering using the Partek software were performed (see Supporting Information for details).

**Real-time polymerase chain reaction analysis**

We isolated total RNA from the quadriceps muscle of sedentary resting (n = 5) and trained mice for 5 days (n = 7), and we performed an analysis by single real-time reverse-transcription polymerase chain reaction (RT-PCR) using TaqMan® Gene Expression Assays probes (Applied Biosystems®, Foster City, CA, USA) according to the manufacturer’s recommendations (see Supporting Information for details).

**GSH and GSSG determination**

We determined GSH and GSSG concentrations in gastrocnemius muscles by a spectrophotometric procedure that uses N-ethylmaleimide (NEM) to minimize thiol auto oxidation during sample preparation.

**Lipid peroxidation determination by high-performance liquid chromatography**

Malondialdehyde (MDA) levels were determined in gastrocnemius samples as described previously (see Supporting Information for details).

**Carbonylated proteins**

Immunoblot detection of protein carbonyl groups in gastrocnemius samples was assessed using the ‘Oxyblot Protein Oxidation Detection Kit’ (Millipore, USA) (see Supporting Information for details).

**Western blotting**

Gastrocnemius samples were homogenized in 10 volumes of lysis buffer and centrifuged at 10 000 g for 10 min (4°C). Sixty micrograms of protein extract were loaded into Stain-Free 4–20% precast gels (4568095; Bio-Rad) before electrophoretic migration and transfer onto nitrocellulose membranes (Bio-Rad; Trans-Blot Turbo Blotting System). Then, the membranes were blocked and incubated overnight at 4°C with primary antibodies. The membranes were then incubated...
for 1 h with a peroxidase-conjugated secondary antibody (see Supporting Information for details).

**High-resolution respirometry**

Mitochondrial respiration was carried out with permeabilized muscle fibre bundles from the soleus muscle of ~20-month-old G6PD-Tg \((n = 4)\) and WT mice \((n = 6)\) using the Oxygraph-2k (see Supporting Information for details).

**In vivo metabolic assessment**

Respiratory metabolism and spontaneous activity and rearing were assessed by indirect calorimetry with the OxyletPro System (Panlab, Harvard Apparatus) in ~20-month-old G6PD-Tg \((n = 5)\) and WT mice \((n = 5)\). Mice were single housed with ad libitum access to food and water and maintained at 20–22°C under a 12:12 h light:dark cycle (light period 08.00–20.00). All mice were acclimated to monitoring cages for 16–18 h prior to recording. Oxygen consumption was determined by measuring oxygen concentration in air entering the chamber compared with air leaving the chamber. Measurement in each chamber was recorded for 1 min at 5 min intervals for a total of 48 h.

**Body composition**

Mice (~20-month-old) body composition (bone mineral density, lean mass, fat mass, and fat in tissue) was analysed with simple anaesthesia using the method of dual-energy X-ray absorptiometry (DXA) with Medikors’ InAlyzer (WT \(n = 6\), Tg \(n = 5\)).

**Haematological measurements**

We used the veterinary ‘Hematology ELEMENT HT5’ and the ‘Skyla VB1’ analyser to provide haematological and biochemical parameters in whole EDTA blood in ~20-month-old G6PD-Tg \((n = 6)\) and WT mice \((n = 8)\) (Supporting Information, Table S1).

**Exercise training**

Young C57Bl/6J mice (5-month-old) were allocated in two different groups: sedentary resting mice \((n = 5)\) and trained mice for 5 days \((n = 7)\). Mice were trained for five consecutive days with the following protocol: treadmill downhill running (−20°) at 10 m/min for 5 min, followed by 25 min at 18 m/min (PanLab Harvard Apparatus, Columbus Instruments LE8708). After 2 days of resting, quadriceps muscles were collected.

**Glucose 6-P dehydrogenase activity**

Glucose 6-P dehydrogenase activity was determined as described previously\(^2^4\) in quadriceps muscle samples of young trained and sedentary resting mice as well as in old WT and G6PD-Tg animals (~20-month-old).

**Statistical methods**

Values are expressed as the mean ± standard deviation (SD). Normal distribution of the samples was assessed by the Shapiro–Wilk test. To compare two different groups, the unpaired Student’s \(t\)-test was used, or the Mann–Whitney test in case of a non-normal distribution. To study two independent variables, a two-way analysis of variance (ANOVA) test was used. For the frailty score and its criteria, differences were tested using the Pearson’s \(\chi^2\) test. A one-way ANOVA was used to determine differences in gene expression between groups. The effect size in the percentage of muscle weight lost with age has been determined performing an \(F\)-test. Statistical analysis was performed using Statistica, SPSS, or GraphPad Prism software, with a significance level set at \(P < 0.05\), and all graphs were represented with GraphPad Prism8 Software.

**Results**

**Old G6PD-Tg mice are less frail than their wild-type congeners**

Using a cohort of female mice (WT and G6PD-Tg) aged 18 to 26 months, we established a frailty score based on the evaluation of five parameters: body weight, motor coordination, maximal grip strength, running time, and running speed achieved during a treadmill test.\(^1^6\),\(^1^7\)

**Body weight**

Mice were weighted every 2 months from 18 to 26 months of age (Supporting Information, Figure S1). To evaluate the loss of weight with aging, we used the mean body weight of the animals at the age of 18 months as initial controls. An animal was considered as frail for this criterion when at any given age, it had lost more than 5% of its weight at the age of 18 months. Compared with the WT, G6PD-Tg mice maintained better their weight with advancing age. At 25–26 months of age, more than 72% of WT mice were considered as frail for this criterion, whereas only 17% in the Tg group was (Figure 1A).
Motor coordination
The tightrope test was used to evaluate motor coordination in mice. The animals that failed the test were considered as frail for this criterion (Figure S1). The G6PD-Tg animals clearly performed better than the WT at the different ages tested. However, the differences only reached statistical significance in the 18- to 20- and 23- to 24-month-old mice. In the WT group, 29% and 42% of the mice failed the test at these specific ages. Only the 2.5% and 6.9% of the G6PD-Tg mice failed the motor coordination test at 18–20 and 23–24 months of age (Figure 1B).

Grip strength
Maximal grip strength was recorded using the grip strength metre, which detects the peak force applied on the device. The values obtained were divided by animal’s body weight. G6PD-Tg mice were stronger than WT mice, especially when they were 23–24 months old (mean scores of 3.9 ± 0.2 in the WT group vs. 5.0 ± 0.1 in the G6PD-Tg group) (Figure S1). Consequently, 50% of the WT animals fulfilled this frailty criterion compared with the 6.9% of the same age G6PD-Tg mice (Figure 1C).

Figure 1 Valencia Score for frailty in WT and G6PD-Tg mice. (A–E) Percentage of mice considered as frail for each of the five parameters tested in the WT and G6PD-Tg groups (A–E). (F) The frailty score was calculated as follows: number of tests failed divided by the total number of tests performed, for each group of mice and ages. Mice were tested at different ages: 18- to 20-month-old (n = 24 WT, n = 39–40 Tg), 21- to 22-month-old (n = 17 WT, n = 36 Tg), 23- to 24-month-old (n = 12–14 WT, n = 28–29 Tg), and 25- to 26-month-old (n = 5–11 WT, n = 16–24 Tg). Statistical significance was assessed using Pearson’s \( \chi^2 \) test. *P < 0.05; **P < 0.01; ***P < 0.001.
Running time
Mice performed an incremental treadmill test until exhaustion to evaluate their endurance capacity (Figure S1). We first determined the maximal running time achieved by the animals at the end of the test. We did not find any significant difference in this frailty parameter between the two groups of mice independently of age. Although a tendency was found in the 21- to 22-month-old animals (P = 0.07), the differences between the groups did not reach statistical significance (Figure 1D).

Running speed
The maximal running speed achieved at the end of the incremental test was also recorded (Figure S1). Slowness is an important component when evaluating frailty in the clinical practice. G6PD-Tg animals were significantly faster than the WT ones when they were 21–22 months old (P < 0.05). At this specific age, we found that 41% of the WT mice fulfilled the frailty criterion of slowness while only 13.8% of G6PD-Tg mice did (Figure 1E).

Frailty score
We established a score for frailty based on the results obtained in each of the five parameters measured. In each age group, we divided the total number of tests failed by the total number of tests performed, and we obtained the percentage of mice considered as frail. At each age range (from 18 to 26 months old), the G6PD-Tg mice were less frail than the WT. The most convincing difference was found in the older mice (25–26 months), where almost half of the WT mice were frail vs. only 13% in the G6PD-Tg group (Figure 1F).

Regenerative capacity of muscle stem cells in G6PD-Tg vs. wild-type animals
The activity of G6PD increases dramatically during the regeneration of skeletal muscle, a process highly dependent on satellite cells. Thus, we analysed the regenerative capacity of satellite cells in young WT and Tg animals in response to cardiotoxin-induced muscle injury. We found a loss of the muscle architecture in the injured tibialis anterior muscle at 4 days post-injury, due to the necrosis of myofibres and the activation of an inflammatory response (data not shown). The cross-sectional area of the newly forming myofibres at 7 and 10 days post-injury in both WT and G6PD-Tg mice was lower than in basal conditions, as expected in regenerating, not fully matured myofibres (Figure 2A). The frequency distribution of regenerating fibres by size was not different between G6PD-Tg and WT mice (Figure 2B). Signs of advanced muscle regeneration, as indicated by the appearance of large central-nucleated fibres, can be seen in Figure 2C. All those changes confirmed that the cardiotoxin injection was effective in the induction of muscular damage followed by regeneration. The expression of embryonic myosin heavy chain (eMHC), an early marker of muscle regeneration, indicates new myofibre formation. Newly regenerating myofibres were stained with an anti-eMHC antibody at 4 days post-injury (Figure 2F). No significant differences were found between WT and G6PD-Tg mice in the size of positive myofibres for eMHC staining (eMHC+) (Figure 2D) or in the frequency distribution according to their size (Figure 2E). However, the observed trend of increased eMHC+ fibre size in young Tg animals, together with the fact that frailty is a geriatric syndrome, prompted us to undertake a further study in old mice.

As in young animals, we did not find significant differences in myofibre cross-sectional area between WT and G6PD-Tg old mice at 7 or 10 days post-injury (Figure 3A). The frequency distribution of fibre size was not significantly different between the groups either (Figure 3B). Signs of advanced muscle regeneration are shown in Figure 3C. Newly regenerating myofibres in tibial anterior muscles were positive for eMHC expression at 4 days post-injury (Figure 3F). As reported in young animals, no significant differences were found between WT and G6PD-Tg old mice in eMHC+ fibre size (Figure 3D) or in the frequency of distribution according to their size (Figure 3E).

Transcriptomic analysis
We performed a global gene expression analysis in skeletal muscle and found a different expression pattern between G6PD-Tg vs. WT animals. Figure 4A shows the PCA in G6PD-Tg and WT muscle samples according to their transcriptome. The PCA score plot showed a 47% variability between the G6PD-Tg and WT groups, and two different clustered groups could be therefore clearly appreciated.

The transcriptomic analysis showed 1653 differentially expressed genes. Of these, 779 genes were up-regulated (47%) and 874 were down-regulated (53%) in the Tg animals when compared with WT. The different pattern of gene expression observed in the PCA was confirmed by dendrogram from unsupervised hierarchical clustering analysis. Figure 4B shows in blue and red the statistically significant down-regulated and up-regulated genes, respectively. WT mice are clustered in the upper zone, and G6PD-Tg mice are clustered in the lower zone. Differentially expressed genes were analysed using the Pathway Studio software. The most representative metabolic pathways identified, in terms of enrichment P value, were as follows: (i) the mitochondrial respiratory chain and oxidative phosphorylation (P value 0.009, nine genes up-regulated in the G6PD-Tg vs. WT) (Figure 4C) and (ii) the glutathione metabolism pathway (P value 0.035, nine genes up-regulated and two genes down-regulated in the G6PD-Tg vs. WT) (Figure 4D). Two
Figure 2 Tibialis anterior muscle regeneration in young WT and G6PD-Tg mice. (A) Quantification of the myofibre size, evaluated by the cross-sectional area, in TA muscle sections in basal conditions and regeneration at 7 and 10 days after cardiotoxin-induced injury in 7-month-old mice (n = 4 WT; n = 4 Tg, for each group). (B) Quantification of fibre cross-sectional area frequency of distribution in muscle sections in basal conditions and regeneration at 7 and 10 days after cardiotoxin-induced injury (n = 4 WT; n = 4 Tg, for each group). (C) Representative images of haematoxylin–eosin staining. (D) Quantification of the eMHC+ myofibre size, evaluated by the cross-sectional area, in tibial anterior sections in regeneration at 4 days after cardiotoxin-induced injury (n = 4 WT; n = 4 Tg, for each group). (E) Quantification of eMHC+ fibre cross-sectional area frequency of distribution (n = 4 WT; n = 4 Tg, for each group). (F) Representative images of eMHC immunostaining. Scale bars, 50 μm. Data bars represent mean ± SD. Dots represent individual data. Statistical significance was assessed using the two-way ANOVA test: **P < 0.01, ****P < 0.0001.
relevant biological processes were also identified: (i) apoptosis ($P$ value $3.53 \times 10^{-7}$, 26 genes down-regulated and 30 genes up-regulated in the G6PD-Tg vs. WT) (Figures 4E and S2) and (ii) the oxidative stress response ($P$ value $5.08 \times 10^{-7}$, 7 genes down-regulated and 13 up-regulated in the G6PD-Tg vs. WT) (Figure 4F). The heatmap for the fold-change values of differently expressed genes for Figure 4C–4E is available in the centre of the figure.

The complete lists of the genes involved in these metabolic pathways and biological processes are shown in Table S2.
Figure 4  Skeletal muscle transcriptomic analysis in old G6PD-Tg and WT mice. (A) Principal component analysis (PCA) showing changes in the transcriptomic profile between 21-month-old G6PD-Tg and WT mice (percentage of variability: 46.7%). (B) Unsupervised hierarchical clustering of the 1653 differentially expressed genes in G6PD-Tg and WT samples. (C) Genes up-regulated in G6PD-Tg vs. WT from the mitochondrial respiratory chain and oxidative phosphorylation pathway. (D) Genes differentially expressed in G6PD-Tg vs. WT from the glutathione metabolism pathway. (E) Genes differentially expressed in G6PD-Tg vs. WT from the apoptotic biological process. (F) Genes differentially expressed in G6PD-Tg vs. WT from the oxidative stress response biological process. (C–F) The fold change is indicated next to the genes’ name, and the heatmap for the fold-change values of differently expressed genes is available in the centre of the figure.
**Improved reactive oxygen species detoxification in skeletal muscle of G6PD-Tg old mice**

Low levels of the reduced (GSH) to oxidized (GSSG) glutathione ratio indicate a lower oxidative stress and improved ROS detoxification.\(^\text{12}\) Figure 5A shows that the GSH levels were significantly higher (34.5%, \(P < 0.01\)) whereas those of GSSG (−69%, \(P < 0.05\)) were significantly lower in the muscles of the G6PD-Tg animals when compared with the WT ones (Figure 5B). Consistently, the GSSG/GSH ratio (Figure 5C) was significantly lower in the G6PD-Tg group.

We next measured protein carbonylation and two products of lipid peroxidation (MDA and 4-HNE), both markers of ROS-derived damage in 21-month-old WT and G6PD-Tg mice. We did not detect any changes in either MDA levels or protein carbonylation (Figure S3), but the levels of 4-HNE were significantly lower (−20.5%, \(P < 0.05\)) in G6PD-Tg muscles (Figure 5D). These results indicate that G6PD overexpression does protect against oxidative stress (glutathione redox ratio) and macromolecular damage through a reduction in the accumulation of oxidized lipids.

**Structural and functional impact of glucose 6-P dehydrogenase overexpression in skeletal muscle mitochondria and apoptosis**

The impact of G6PD overexpression on mitochondrial morphology and functional adaptations was investigated in skeletal muscle in 21- to 25-month-old WT and 23- to 27-month-old G6PD-Tg animals. We found an increase in the protein levels of cytochrome c oxidase IV (COX IV), one of the nuclear encoded subunits of cytochrome c oxidase (COX IV: 89.7%, \(P < 0.05\)), in the Tg mice when compared with WT (Figure 6A and 6B). This result is consistent with the transcriptomic analysis where we found that five of the nine OXPHOS genes up-regulated in the microarrays in the Tg mice encoded COX subunits (Table S2.2). Next, we determined the abundance of mitochondrial OXPHOS complexes in tibialis and gastrocnemius extracts immunoblotted with antibodies specific for protein components of each mitochondrial complex: NADH dehydrogenase (Complex I), succinate dehydrogenase (Complex II), cytochrome b–c1 (Complex III), cytochrome c oxidase (Complex IV), and ATP synthase (Complex

---

**Figure 5**  Markers of oxidative stress in muscles of 21-month-old WT and G6PD-Tg mice. (A) GSH levels (\(n = 8\) WT, \(n = 9\) Tg). (B) GSSG levels (\(n = 6\) WT, \(n = 5\) Tg). (C) GSSG/GSH×100 (\(n = 5\) WT, \(n = 5\) Tg). (D) Marker of oxidative damage to lipids: 4-HNE levels (\(n = 6\) WT, \(n = 7\) Tg). (E) Membrane representing 4-HNE protein blot (top panel) and its corresponding loading control (bottom panel). Bars represent the mean ± SD. Dots represent individual data. Statistical significance was assessed using the unpaired Student’s \(t\)-test. *\(P < 0.05\), **\(P < 0.01\).

Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12792
Figure 6  Mitochondrial skeletal muscle parameters in WT and G6PD-Tg animals. (A) Protein levels of COX IV \( (n=7 \text{ WT}, n=7 \text{ Tg}) \), Grp75 \( (n=7 \text{ WT}, n=7 \text{ Tg}) \), fatty acid binding protein 4 (FABP4) \( (n=6 \text{ WT}, n=6 \text{ Tg}) \), Bax/Bcl2 \( (n=7 \text{ WT}, n=7 \text{ Tg}) \), Bcl-xL \( (n=7 \text{ WT}, n=6 \text{ Tg}) \), and HSP70 \( (n=7 \text{ WT}, n=6 \text{ Tg}) \) (21-month-old mice). COX IV, Grp75, FABP4, and Bax/Bcl2 were referenced to their stain-free loading control. Bcl-xL and HSP70 were referenced to \( \alpha \)-actin. (B) Membranes representing COX IV, Grp75, Bax, Bcl2, FABP4, Bcl-xL, HSP70, and \( \alpha \)-actin western blots. (C) Multi-protein OXPHOS levels determined in tibialis anterior muscle \( (n=11 \text{ WT}, n=12 \text{ Tg}) \) (top panel) and gastrocnemius muscle \( (n=6 \text{ WT}, n=7 \text{ Tg}) \) (bottom panel) (21- to 27-month-old mice). (D) Representative image of SUIT 8 Oroboros respiratory experiment. (E) Oxygen flow of skeletal muscle bundles \( (n=6 \text{ WT}, n=4 \text{ Tg}) \) (20-month-old mice). Data bars represent the mean ± SD, and dots the individual data. Statistical significance was assessed using the unpaired Student’s t-test. *\( P < 0.05 \), **\( P < 0.01 \), ***\( P < 0.001 \).
V). G6PD-Tg mice exhibited higher expression of Complex II (81.25%, \( P < 0.01 \)) and Complex III (52.5%, \( P < 0.01 \)) in tibialis and Complex V (37.2%, \( P < 0.05 \)) in gastrocnemius, when compared with the WT (Figure 6C). Original gels and stained membranes are shown in Figure S4.

Mitochondrial respiration was carried out with permeabilized muscle fibre bundles from soleus muscle in ~20-month-old G6PD-Tg (\( n = 4 \)) and WT mice (\( n = 6 \)) using the Oxygraph-2k. Overexpression of G6PD did not significantly alter the mitochondrial respiration values, although a slightly higher mitochondrial respiration was observed when the Complex IV activity was assayed in the Tg animals when compared with the WT (Figure 6D and 6E).

We also determined the protein levels of GRP75 (Figure 6A and 6B), a mitochondrial chaperone involved in the refolding of redox-modified proteins.\(^\text{27}\) It was significantly increased in the G6PD-Tg compared with WT mice (37.8%, \( P < 0.05 \)). GRP75 is a well-known inhibitor of apoptosis through the modulation of the apoptosis indicator BAX/BCL-2 ratio.\(^\text{28}\) The BAX/BCL-2 ratio was also significantly reduced (–25.5%, \( P < 0.05 \)) in the Tg animals (Figure 6A and 6B). It was accompanied with an increase in Bcl-xL (20.5%, \( P < 0.05 \)), a member of the Bcl-2 family of proteins that acts as an anti-apoptotic protein. Although we did not find changes in Hsp70 protein levels, a chaperone with anti-apoptotic properties, our results altogether show lower activity of apoptotic processes in mice overexpressing G6PD. These data indicate that G6PD overexpression is associated with an up-regulation of survival/anti-apoptotic factors (Figure S2).

To evaluate the accumulation of intramuscular fat, we measured the expression of FABP4,\(^\text{29}\) a marker of mature adipocytes, and found significantly lower levels of its expression (–54.7%, \( P < 0.05 \)) in the skeletal muscle of Tg animals when compared with the WT ones (Figure 6A and 6B).

**Body composition and metabolic measurements in old G6PD-Tg and wild-type mice**

Using metabolic cages, we quantified the energy expenditure (EE), the ambulatory activity, and the respiratory exchange ratio (RER) to determine relative use of carbohydrates or lipids for EE in old mice (~20-month-old) (Figure 7A, 7C, and 7E).\(^\text{30}\) G6PD-Tg animals exhibited lower RER than their WT counterparts indicating oxidation of lipids (WT: \( L: 0.89 \pm 0.03, D: 0.95 \pm 0.02 \); G6PD-Tg: \( L: 0.77 \pm 0.03, D: 0.82 \pm 0.02 \))\(^\text{31}\) (Figure 7B, right panel). The EE-area under the curve (EE-AUC) was also significantly diminished in the Tg mice vs. the WT ones (Figure 7D, right panel). Moreover, old G6PD-Tg mice exhibited a clear increase in locomotor activity, which, comparatively, was absent in the WT animals (Figure 7F, right panel).

Using DXA, we did not find changes in body composition (fat, lean, and bone data) (Figure S5) or in blood biochemical and haematological parameters that could explain the reported differences as a function of the genotype (Table S1).

However, when we assessed the cross-sectional area of muscle fibres from very old mice (34-month-old) (Figure 7G and 7H), we found that G6PD-Tg mice had a larger muscle fibre size compared with the WT (1005.5 vs. 901.5 \( \mu m^2 \), respectively, \( P < 0.05 \)). Moreover, we weighted different muscles longitudinally in 6-, 11-, and 23-month-old Tg and WT mice (Figure S5B). We found that the percentage of muscle weight lost in gastrocnemius muscle, in 6 vs. 23 months old, was significantly lower in G6PD-Tg when compared with WT mice (\( P < 0.004 \)) (Figure 7I).

**Exercise training as a physiological intervention to increase glucose 6-P dehydrogenase activity**

Exercise training is a cost-effective, clinically proven intervention that can delay and even prevent frailty.\(^\text{32}\) We found a significant increase in the mRNA levels of G6PD (127.6%, \( P < 0.01 \)) in C57BL/6J young mice after a short period (5 days) of eccentric exercise training (Figure 8A). This was accompanied with a robust increase in the activity of G6PD in skeletal muscle (rest: 0.46 ± 0.16 nmol/min × mg of protein vs. 5 days trained: 1.41 ± 0.78 nmol/min × mg of protein) (Figure 8B). Very interestingly, the improvements in the G6PD activity achieved with the exercise training were very similar to that obtained in the mouse harbouring a copy of the complete human G6PD gene (G6PD-Tg: 0.99 ± 0.50 nmol/min × mg of protein, WT: 0.41 ± 0.12 nmol/min × mg of protein; \( P < 0.01 \)) (Figure 8C).

**Discussion**

**Delivering the onset of frailty by the overexpression of glucose 6-P dehydrogenase**

Frailty has such a relevance in both clinical medicine that finding interventions to delay it is of utmost importance. Several models have been proposed to accelerate the onset of frailty.\(^\text{8,33}\) However, to our knowledge, a defined molecular model to delay frailty and promote vigorousness has not yet been proposed. Improvements in ‘neuromuscular healthspan’ have been reported with resveratrol,\(^\text{34}\) caloric restriction,\(^\text{35}\) rapamycin,\(^\text{36}\) or exercise.\(^\text{16}\) Moreover, the HSP70 overexpressing mice\(^\text{14}\) and the GHR-KO mice\(^\text{15}\) have shown to delay primary sarcopenia or even senescence, but frailty has not been assessed in these models.

The early frailty models were based on the idea that promoting inflammation by knocking-out anti-inflammatory cytokines [such as interleukin (IL)-10] could accelerate the...
Figure 7  Impact of G6PD overexpression on whole-body skeletal muscle physiology and in vivo metabolism in old mice. (A) Respiratory exchange ratio over 48 h (RER) \((n = 6 \text{ WT, } n = 5 \text{ Tg})\). (B) (left) RER average data from the two light (L1 + L2) and dark (D1 + D2) cycles \((n = 6 \text{ WT, } n = 5 \text{ Tg})\). (right) Area under the RER curve. (C) Energy expenditure (EE) over 48 h \((n = 6 \text{ WT, } n = 5 \text{ Tg})\). (D) (left) EE average data from the two light (L1 + L2) and dark (D1 + D2) cycles \((n = 6 \text{ WT, } n = 5 \text{ Tg})\). (right) Area under the EE curve. (E) Voluntary ambulatory activity over 48 h section \((n = 6 \text{ WT, } n = 5 \text{ Tg})\). (F) (left) Voluntary ambulatory activity average data from the two light (L1 + L2) and dark (D1 + D2) cycles \((n = 6 \text{ WT, } n = 5 \text{ Tg})\). (right) Area under the voluntary ambulatory activity curve. (G) Cross-sectional area measurement of muscles fibres (\(\mu m^2\)) of very old mice, that is, 34 months of age \((n = 8 \text{ WT, } n = 7 \text{ Tg})\). Data bars represent the mean ± SD. (H) Representative images of haematoxylin–eosin colouration used to quantify cross-sectional area. (I) Percentage of gastrocnemius muscle weight lost from 6- to 23-month-old G6PD-Tg and WT mice. The effect size has been determined using the F-test. \(^{**}P < 0.001, \text{****}P < 0.0001\).
onset of frailty. However, as stated earlier, not one single molecular model has shown to delay the onset of frailty.

Glucose 6-P dehydrogenase is tightly regulated, but we have shown here that it can be modulated by a physiological intervention such as exercise training. We report that only 5 days of eccentric exercise training induces a robust increase in both the mRNA levels and the G6PD activity in skeletal muscle in mice. These increments are similar to those obtained in the G6PD-Tg mice that display a ubiquitous two-fold to four-fold overexpression of G6PD mRNA and also show an equivalent increase in G6PD activity. The exercise-induced increase in the endogenous antioxidant protection may generate a cellular hyper-defensive state being one of the molecular bases of the reported beneficial effects of exercise in the prevention of frailty.

Glucose 6-P dehydrogenase can also be modulated by nutritional and pharmacological interventions. Although no medications are available to treat G6PD deficiency, recently, it has been identified a small molecule, AG1, that increases the activity of several common G6PD mutants by improving the binding of NADP+ and/or G6P to the enzyme. AG1 reduces oxidative stress in cells and zebrafish and also decreases diamide-induced oxidative stress in human erythrocytes. AG1 corrects G6PD deficiency but also seems to be suitable to treat subjects with WT G6PD at risk of oxidative stress-related diseases.

**Glucose 6-P dehydrogenase-dependent promotion of robustness does not involve improvement in muscle regeneration**

We studied the skeletal muscle stem cells regenerative capacity as a possible mechanism that could underlie the observed delay in frailty in the G6PD-Tg mice. Satellite cell regenerative functions decline with aging due to an entry in a senescence state leading to frailty/sarcopenia. G6PD production of NADPH is critical for redox control and cell growth. However, we did not find differences in the regenerative functions of satellite cells from G6PD-Tg and WT animals after muscle injury in any of the ages studied.

Satellite cell-mediated myonuclear accretion has a major role in maturational skeletal muscle growth and during injury-induced skeletal muscle regeneration. However, their contribution to the homeostasis of adult fibres has been an object of debate, and its role in the regulation of muscle mass has been questioned by several experimental evidences. In fact, short-term deletion of satellite cells in adult mice does not result in muscle fibre atrophy, and sarcopenia is generally not exacerbated, reinforcing the notion that satellite cells serve primarily muscle regenerative functions. Consistent with this, our results minimize the contribution of muscle satellite cells regenerative potential to the delayed onset of frailty in the G6PD-Tg mice.

**In old G6PD-Tg mice, age-associated metabolic changes are prevented**

Based on our transcriptomic analysis, we explored several possible mechanisms that could underlie the protective effect of G6PD in terms of frailty. We found a significant decrease in the BAX/BCL-2 ratio and an increase in Bcl-xl in the skeletal muscle of the G6PD-Tg mice, indicating lower activity of apoptotic processes in the animals overexpressing the
antioxidant enzyme. Several signalling pathways of skeletal muscle apoptosis are currently under intense investigation, with a particular focus on the role played by mitochondria. During aging, there is an impairment in cellular mitochondrial function that contributes to muscle atrophy and the decline in muscle performance observed in frail old individuals. This functional decline is associated with substantial reduction in respiratory capacity, ATP production, as well as increased apoptosis. Pathways enriched in genes involved in mitochondrial respiratory chain and mitochondrial genome maintenance are among the most down-regulated ones during aging. In our study, from the nine OXPHOS genes found up-regulated in the microarrays of the G6PD-Tg mice, five of them encoded COX subunits. This result correlates with the higher GRP75 and COX IV levels found in the 21-month-old Tg animals. Poor physical performance in the elderly is associated with a greater decline in mitochondrial respiration as well as COX muscle activity. On the contrary, overexpression of G6PD is associated with a significant increase in the protein levels of COX IV and an improvement in functional parameters in old animals. Consistent with these results, G6PD-Tg mice also exhibited higher expression of Complexes II, III, and V in skeletal muscle, when compared with the WT. Fatty acid oxidation generates FADH2, which is a substrate of Complex II. The up-regulation of Complex II in the Tg animals matches with the indirect calorimetry results. The lower RER-AUC data reveal that old G6PD-Tg animals utilize more lipids than carbohydrates as substrates. Individuals, both humans and rodents, with sedentary lifestyles normally have higher RER values and lower fat oxidation. On the contrary, physically active individuals tend to show lower RER values than untrained ones. Previous studies have shown that old C57BL/6J mice have higher RER levels when compared with young ones, indicating a preference towards carbohydrate utilization. We have also found that the Tg animals show a reciprocal pattern of a lower EE and higher ambulatory activity, indicative of major energetic advantage from an underlying remodelling of gene expression and metabolism in contracting skeletal muscle.

Dysfunctional mitochondria are characterized by an excessive production of ROS, which oxidize and damage macromolecules. We reasoned that the mechanism by which the overexpression of G6PD delays frailty consisted in the alleviation of the load of oxidative damage associated with aging. Indeed, we observed that age-dependent accumulation of oxidized lipids in the skeletal muscle was diminished in the G6PD-Tg mice. This was accompanied with a decrease in the intramuscular adipose tissue levels or fatty acid infiltrations (FABP4) in the Tg animals. Our hypothesis was further supported by the observation that the levels of GSH were increased in the transgenic animals while those of the GSSG were significantly decreased in skeletal muscle. Together, these findings reinforce the notion that G6PD delays the onset of frailty by protecting against muscle damage, especially oxidative damage, and not by decreasing muscle regeneration.

We previously showed that oxidative stress is associated with frailty and not with aging itself. Support for the idea of the ‘free radical theory of frailty’ came from a study showing that mice with a deletion of the antioxidant enzyme superoxide dismutase presented signs of muscle weakness, atrophy, and sarcopenia. However, the contrary proposal, that is, that animals protected against oxidative stress could show delayed onset of frailty and increase robustness, had not been tested.

The G6PD-Tg mouse that we describe here is the first defined molecular model to show protection against frailty and promotion of robustness. Our experiments, together with those reported in our previous study, provide support to the idea that damage associated with ROS is involved in the onset of frailty.

Clinical implications

Glucose 6-P dehydrogenase activation increases pentose availability and antioxidant capacity, the former being important in DNA and RNA synthesis and the latter due to the formation of NADPH. This enzyme has several clinical implications. G6PD deficiency is the most common enzyme deficiency in humans. It affects over 400 million people in the world especially in those areas where malaria is common. In addition to the role of G6PD in preventing haemolysis, the antioxidant properties of this enzyme may relate to development of a variety of other age-associated pathologies, including kidney injury, heart failure, diabetes, and cataracts, suggesting that G6PD deficiency can be an underestimated risk factor for multiple human pathologies and even frailty.

Based on our findings, whether people affected by partial deficiencies of G6PD may be more prone to frailty should be explored in future studies. In view of our results, the activation of the G6PD activity by nutritional, pharmacological, and physiological interventions such as exercise may have translational potential in geriatrics and in gerontological research.

Limitations of the study

The fact that we could not perform all the frailty measurements in every mouse of the Tg and WT cohorts is a limitation of our study especially because it made impossible for us to establish an individual score of frailty. Our model does not allow us to identify pre-frail mice. It only provides us a binary information because we have to identify normal values for each set of mice. The identification of standard physical parameters for each strain of mice would be highly desirable but indeed a daunting task because of the large number of animals required.
Acknowledgements

We thank Dr. Jose Manuel Martí (Berkeley Lab) for his assistance with the digital image acquisition and processing work. We thank Marilyn Noyes for reviewing the English aspects of this work.

The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.46

Funding

This work was supported by Instituto de Salud Carlos III CB16/10/00435 (CIBERFES) (PID2019-110906RB-I00/AEI/10.13039/501100011033) from the Spanish Ministry of Innovation and Science; 109_RESIFIT from Fundación General de la Sanitat de la Generalitat Valenciana’ and EU Funded H2020-DIABFRAIL-LATAM (Ref: 825546); European Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ (JPI HDHL); and the ERA-NET Cofund ERA-HDHL (GA No. 696295 of the EU Horizon 2020 Research and Innovation Programme). Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana 2014–2020).

Work in the laboratory of P.J.F.-M. was funded by the FBBVA and the Ramón Areces Foundations. Work in the laboratory of P.M.-C. and A.L.S was funded by by MWRF and Fundació La Marató/TV3-80/19-202021 to P.M.C. and Fundació La Marató de TV3 (Project 202033 to A.L.S.), MINECO-Spain (RTI2018-096068), ERC-2016-AdG-741966, LaCaixa-HEALTH-HR17-00040, MDA, UPGRADE-H2020-825825, AFM, and DPP-Spain; María-de-Maeztu-Program for Units of Excellence to UPF (MDM-2014-0370); and Severo-Ochoa-Program for Centers of Excellence to CNIC (SEV-2015-0505). A.S.-P. was supported by a fellowship from the Spanish ‘Ministerio de Educación, Cultura y Deporte’, award FPU 14/00098.

Online supplementary material

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Conflict of interests

The authors declare no competing financial interests.

References

1. Vina J, Tarazona-Santabalbina FJ, Perez-Ros P, Martínez-Arnau FM, Borras C, Olaso-Gonzalez G, et al. Biology of frailty: modulation of ageing genes and its importance to prevent age-associated loss of function. Mol Aspects Med 2016;50:88–108.
2. Vina J, Borras C, Gomez-Cabrera MC. A free radical theory of frailty. Free Radic Biol Med 2018;124:358–363.
3. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56: M146–M156.
4. Mathieu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, et al. Delayed ageing through damage protection by the Art/p53 pathway. *Nature 2007;448:375–379.

5. Ingles M, Gambini J, Canicero JA, Garcia-Garcia FJ, Rodriguez-Manas L, Olsos-Gonzalez G, et al. Oxidative stress is related to frailty, not to age or sex, in a geriatric population: lipid and protein oxidation as biomarkers of frailty. *J Am Geriatr Soc 2014;62:1324–1328.

6. Saum KU, Dieffenbach AK, Jansen EH, Schottker B, Holleczek B, Hauer K, et al. Association between oxidative stress and frailty in an elderly German population: results from the ESTHER cohort study. *Gerontology 2015;61:407–415.

7. Deepa SS, Bhaskaran S, Espinoza S, Brooks SV, McArthe A, Jackson MJ, et al. A new mouse model of frailty: the Cu/Zn superoxide dismutase knock-out mouse. *Gerasencience 2017;39:187–198.

8. Walston J, Fedarko N, Yang H, Leng S, Beamer B, Espinoza S, et al. The physical and biological characterization of a frail mouse model. *J Gerontol A Biol Sci Med Sci 2008;63:443–450.

9. Ghersuovicov JM, Garcia-Cañaveras JC, Wang J, Schmidt E, Zhang Z, TeSlaa T, et al. A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway. *Nat Biotechnol 2020;38:731–739.

10. Fernandez-Marcos PJ, Nóbrega-Pereira S, NADPH: new oxygen for the ROS theory of ageing. *Oncotarget 2016;7:50814–50815.

11. Legan SK, Rebrin I, Mockett RJ, Radyun SN, Klichko VI, Sohal RS, et al. Overexpression of glucose-6-phosphate dehydrogenase extends the lifespan of Drosophila melanogaster. *J Biol Chem 2008;283:32492–32499.

12. Nóbrega-Pereira S, Fernandez-Marcos PJ, Brioche T, Gomez-Cabera MC, Salvador-Pascual A, et al. G6PD protects against oxidative damage and improves healthspan in mice. *Nat Commun 2016;7:10894.

13. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. *Lancet 2008;371:64–74.

14. Broome CS, Kayani AC, Palomero J, Dillmann WH, Mestril R, Jackson MJ, et al. Effect of lifelong overexpression of Hsp70 in skeletal muscle on age-related oxidative stress and adaptation after nondamaging contractile activity. *FASEB J 2006;20:1549–1551.

15. Arum O, Rickman DJ, Kophcich JJ, Bartke A. The slow-aging growth hormone receptor/binding protein gene-disrupted (GHR-KO) mouse is protected from aging-related neuromusculoskeletal frailty. *Age (Dordr) 2014;36:117–127.

16. Gomez-Cabera MC, Garcia-Valles R, Rodriguez-Manas L, Garcia-Garcia FJ, Olsos-Gonzalez G, Salvador-Pascual A, et al. A new frailty score for experimental animals based on the clinical phenotype: inactivity as a model of frailty. *J Gerontol A Biol Sci Med Sci 2017;72:885–891.

17. Martinez de Toda I, Garrido A, Vida C, del Pino-Vela L, Pascual A, et al. G6PD protects oxidative stress in regenerating skeletal muscle. *Oncotarget 2017;8:1549–1551.

18. Katare R, Caporali A, Emanueli C, Madea M, Benfotiamine improves functional recovery of the infarcted heart via activation of pro-survival G6PD/Akt signaling pathway and modulation of neurohumoral response. *J Mol Cell Cardiol 2010;49:625–630.

19. Hwang S, Mruk K, Rahighi S, Raub AG, Chen CH, Dorn LE, et al. Correcting glucose-6-phosphate dehydrogenase deficiency with a small molecule activator. *Nat Commun 2018;9:4045.

20. Brioche T, Kireev RA, Cuesta S, Gratas-Delamarce A, Tresguerres JA, et al. Growth hormone replacement therapy prevents sarcopenia by a dual mechanism: improvement of protein balance and of antioxidant defenses. *J Gerontol A Biol Sci Med Sci 2014;69:1186–1198.

21. Suelles MV, Choy KW, Wei M, Cheng CW, Sedrakyan S, Navarrete G, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. *Cell Metab 2015;22:86–99.

22. Correa-Melo C, Birch J, Fielder E, Rahmatika D, Taylor J, Chapman J, et al. Rapamycin improves healthspan but not in-flammaging in mdx mice. *Aging Cell 2018;17:e12882.

23. Murach KA, Fry CS, Kirby TJ, Jackson JR, Lee JD, White SH, et al. Starring or supporting role? Satellite cells and skeletal muscle fiber size regulation. *Physiology (Bethesda) 2018;33:26–38.

24. Lepper C, Partridge TA, Fan CM. An absolute requirement for Pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration. *Development 2011;138:3639–3646.

25. Sambasivan R, Yao R, Kissenpffennig A, Van Wittenberge L, Paldi A, Gayraud-Morel B, et al. Pax7-expressing satellite cells are indispensable for adult skeletal muscle muscle regeneration. *Development 2011;138:3647–3656.

26. Derbre F, Gomez-Cabera MC, Nascimento AL, Sanchis-Gomar F, Martinez-Bello VE, Tresguerres JA, et al. Age associated low mitochondrial biogenesis may be explained by lack of response of PGC-1α to exercise training. *Age (Dordr) 2011;34:669–679.

27. Gonzalez-Freire M, de Cabo R, Bernier M, Sollott SJ, Fabbri E, Navas P, et al. Reconsidering the role of mitochondria in aging. *J Gerontol A Biol Sci Med Sci 2015;70:1334–1342.

28. Joseph AM, Adhithetty PJ, Buford TW, Wolum JM, Lees HA, Nguyen LM, et al. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. *Aging Cell 2012;11:801–809.

-sex-dependent benefits on body composition and metabolism during aging. *Physiol Rep 2016;4:e13011.

29. Houtkooper RH, Argmann C, Houten SM, Canto C, Jeninga EH, Andreux PA, et al. The metabolic footprint of aging in mice. *Sci Rep 2013;1:134.

30. Tarazona-Santabalbina FJ, Gomez-Cabera MC, Perez-Ros P, Martinez-Arnau FM, Cabo H, Tsaakaras P, et al. A multicomponent exercise intervention that reverses frailty and improves cognition, emotion, and social networking in the community-dwelling frail elderly: a randomized clinical trial. *J Am Med Dir Assoc 2016;17:426–433.

31. Kurz D, Wilson C, Passos JF, Oakley F, Correia-Melo C, Greaves L, et al. Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. *Nat Commun 2014;5:2172.

32. Kane AE, Hilimer SN, Boyer D, Gavín K, Nines D, Howlett SE, et al. Impact of longevity interventions on a validated mouse clinical frailty index. *J Gerontol A Biol Sci Med Sci 2016;71:333–339.

33. Rogers JA, Kishi Y, Wei M, Cheng CW, Sedrakyan S, Navarrete G, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. *Cell Metab 2015;22:86–99.

34. Correia-Melo C, Birch J, Fielder E, Rahmatika D, Taylor J, Chapman J, et al. Rapamycin improves healthspan but not inflammation in mdx mice. *Aging Cell 2018;17:e12882.
43. Viña J, Olaso-Gonzalez G, Arc-Chagnaud C, De la Rosa A, Gomez-Cabrera MC. Modulating oxidant levels to promote healthy aging. *Antioxid Redox Signal* 2020;33:570–579.

44. Sathyan S, Ayers E, Gao T, Milman S, Barzilai N, Verghese J. Plasma proteomic profile of frailty. *Aging Cell* 2020;19:e13193.

45. Viña J, Borras C, Gomez-Cabrera MC. A free radical theory of frailty. *Free Radic Biol Med* 2018;124:358–363.

46. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the *Journal of Cachexia, Sarcopenia and Muscle*: update 2019. *J Cachexia Sarcopenia Muscle* 2019;10:1143–1145.